**Name of Journal:** *World Journal of Transplantation*

**Manuscript NO:** 56847

**Manuscript Type:** EDITORIAL

**Torque teno virus in liver diseases and after liver transplantation**

Mrzljak A *et al*. Torque teno virus and liver

Anna Mrzljak, Tatjana Vilibic-Cavlek

**Anna Mrzljak,** Department of Medicine, Merkur University Hospital, School of Medicine, University of Zagreb, Zagreb 10000, Croatia

**Tatjana Vilibic-Cavlek,** Department of Virology, Croatian Institute of Public Health; School of Medicine, University of Zagreb, Zagreb 10000, Croatia

**Author contributions:** Mrzljak A and Vilibic-Cavlek T conceived and designed the study and were involved in drafting and revising the manuscript critically; Both authors approved the final manuscript.

**Corresponding author: Anna Mrzljak, MD, PhD, Associate Professor,** Department of Medicine, Merkur University Hospital, School of Medicine, University of Zagreb, Zajčeva 19, Zagreb 10000, Croatia. anna.mrzljak@gmail.com

**Received:** May 16, 2020

**Revised:** September 22, 2020

**Accepted:** October 9, 2020

**Published online:** November 28, 2020

**Abstract**

Torque teno virus (TTV) has been proposed as a surrogate biomarker for immune monitoring in different patient cohorts. Historically, TTV has been associated with different liver diseases such as post-transfusion hepatitis, hepatitis B, and hepatitis C, but the virus's pathogenicity is controversial. TTV is a ubiquitous DNA virus, highly prevalent and mostly indolent in the general population. Thus, TTV viral load is more relevant than prevalence to understand TTV infection. In the context of liver transplantation, TTV viral load is modulated by the immune, viral, and inflammatory status. After liver transplantation, the TTV viral load positively correlates with the intensity of immunosuppression (IS), and low TTV viral burden is a predictor of acute rejection episodes, making it an attractive marker for the efficacy of IS. However, the TTV role as a single or a panel biomarker needs to be evaluated in further independent prospective trails.

**Key Words:** Torque teno virus; Solid-organ transplantation; Biomarker; Liver disease; Liver transplant; Immune system

**Citation:** Mrzljak A, Vilibic-Cavlek T. Torque teno virus in liver diseases and after liver transplantation. *World J Transplant* 2020; 10(11): 291-296

**URL:** https://www.wjgnet.com/2220-3230/full/v10/i11/291.htm

**DOI:** https://dx.doi.org/10.5500/wjt.v10.i11.291

**Core Tip:** Torque teno virus (TTV) is a ubiquitous, highly prevalent, and mostly indolent DNA virus in the general population. Historically, it has been associated with different liver diseases, but the virus's pathogenicity is controversial. TTV viral load is modulated by immune, viral, and inflammatory status. TTV viral load positively correlates with the intensity of immunosuppression, making it an attractive surrogate biomarker for immune monitoring in different patient cohorts, including liver transplant recipients. However, the TTV role as a single or a panel biomarker needs to be evaluated in further trials.

**INTRODUCTION**

The presence of torque teno virus (TTV) DNA has been proposed as a novel and attractive surrogate biomarker for the efficacy of immunosuppression in different patient cohorts[1-3]. In solid-organ transplant recipients, immunosuppressive therapy is aimed to prevent rejection and increase organ and patient survival. Usually, a combination of drugs with different action mechanisms is used to control the immune system and prevent/treat the rejection[4,5]. However, the immune monitoring strategies are still based on rough surrogates such as the immunosuppressive drug levels, liver function tests, and biopsies. Other currently available tools are still suboptimal or impractical for the assessment of personalized immune system control[6-8]. In an attempt to optimize the immune system's control, a search for an optimal monitoring tool (*e.g*., a biomarker) is an ongoing challenge.

**TTV**

TTV is a non-enveloped, circular single-strand deoxyribonucleic acid (DNA) virus, first identified in Japanese patients with acute post-transfusion hepatitis in 1997[9]. TTV is a member of the Anellovirus family, together with two additional viruses, torque teno mini virus and torque teno midi virus, thus named because of their smaller genomes[10]. Its biological significance is still unknown and evolving. TTV has a high genetic diversity with five genogroups and 29 genotypes identified so far[11]. TTV is ubiquitous, present in water, air, soil, and different human samples[12,13]. The virus's replication has been demonstrated in hematopoietic cells, mononuclear cells and granulocytes, lymphocytes, hepatocytes, and lungs[14-19], reaching far beyond the initially assumed viral hepatotropism. There is no generally standardized diagnostic algorithm for TTV. Polymerase chain reaction (PCR) methods that target TTV can be distinguished as universal, which amplifies most, if not all, the human TTVs, and species-specific, which permits grouping of the virus in one of the 29 TTV genotypes. The diagnosis is focused on the possible pathologic consequence of TTV infection and is performed to measure the kinetics of TTV viremia in selected populations, such as patients treated with immunosuppressive therapy[12].

**TTV AND LIVER DISEASES**

The first reports on TTV showed low prevalence rates in the general population and patients with liver diseases, most likely due to the use of inappropriate PCR primers[20]. More recent reports demonstrate significantly higher prevalence rates in various liver patients: 77% hepatitis C virus (HCV), 77.7 % hepatitis A virus, 87.6% hepatitis E virus(HEV) and 92% non-A-E hepatitis patients[21]. Historically TTV, has been associated with different liver diseases from post-transfusion hepatitis, HCV, and hepatitis B virus (HBV); however, the pathogenicity of the virus is controversial[13]. The fast-growing evidence shows that the virus infects a great majority of people without causing overt disease. More recent epidemiological studies showed that TTV viremia prevalence rates are over 80%-90% in some populations[22-25], with higher viral load in immunosuppressed patients compared to a healthy population[26]. In addition, the results of one Italian study suggested TTV's role in immune senescence and the prediction of all-cause mortality risk in the elderly. Three-year survival differed significantly by TTV load in a cohort of 379 elderly subjects. The proportion of patients that died after 3 years was estimated to be 21.9% for patients with TTV DNA copies ≥ 4.0 log and 5.4% for patients with TTV copies < 4.0 log. These results indicated that TTV may represent an additional virus that establishes latency after primary infection and reactivates in aging when the immune system is compromised[27].

**TTV AND LIVER TRANSPLANTATION**

Regardless of the high prevalence and mostly indolent role in the general population, the TTV role in immunocompromised populations needs to be further elucidated. Given the high global prevalence, TTV viral load is more relevant than the prevalence itself to understand the TTV infection[28]. In patients with compromised immune response, TTV viral load increases as the replication of the virus is inversely correlated with the number and function of T lymphocytes[26,29-31]. A substantial body of evidence supports that TTV is more an associated co-factor, but not a major pathogen itself, in the development of post-transplant outcomes. In immunocompromised patients, the low TTV viral burden has been associated with the development of acute rejection episodes in populations after different organ transplantations[32-34]. In addition, higher TTV levels, isolated from the post-transplant lymphoproliferative disease (PTLD) tissues, are shown to predict independently predict death within 5 years of PTLD diagnosis[35]. Studies show that TTV viral load is modulated by immune, viral, and inflammatory status after liver transplantation (LT). Studies evaluating TTV viral load in pediatric[28] and adult LT[3,26,30,36-39] provided evidence that in the early post-LT period, the viral load is higher than before the transplant. Accordingly, the TTV viral load positively correlates with the intensity of immunosuppression[3,26,37]. It progressively increases and peaks around 3 mo post-transplant[3,26,30,37]. After that, the viral load declines, reflecting the progressive reduction of immunosuppressive drugs, to reach a baseline level, on average, after the 1st year of transplant[3]. The viral load is lower in patients with post-LT chronic hepatitis and HEV immunoglobulin M/immunoglobulin G positive patients[28], possibly because the liver is one of the sites of TTV replication. The TTV viral load, however, is not associated with the level of liver enzymes[28]. The pre-transplant TTV status inversely correlates with the acute cellular rejection (ACR) episodes, suggesting that higher immunocompetence in TTV negative patients before the transplant could be responsible for the higher incidence of ACR within 1 year post-LT[38]. Moreover, as confirmed in other transplant populations, lower TTV viral load is associated with the ACR in LT recipients. TTV DNA shows high sensitivity and negative predictive value in the diagnosis of ACR and therefore could be regarded as a non-invasive tool to rule out moderate ACR episodes[3]. Besides, TTV viral loads are associated with the recipient cytomegalovirus (CMV) status; lower levels are present in CMV negative patients[3,30], and early TTV viral load (0-10 d post-LT) is a predictor of CMV reactivation within first 4 mo post-LT[30]. In the context of HBV reactivation in immunocompromised patients including LT recipients, TTV viral load in addition to HBV viral load and HBV genotype are not associated with the development of acute liver/graft failure[40]. Multiple genogroups are frequently found in a single individual infected with TTV. Their distribution differs before and after transplantation, yet it does not affect LT outcomes[28]. Major key points of the LT studies are presented in Table 1.

**CONCLUSION**

Sophisticated and non-invasive tools to define and/or predict properly the immune-related events in the post-transplant period are still lacking. The currently available instruments are based on the occurrence of robust clinical events such as rejection or infection episodes. The development and implementation of non-invasive and reliable biomarkers to personalize the immune system's control after transplant remain a challenge. In a search for such a biomarker, collaborative effort over the past decade has brought TTV to the frontline of the medical literature as a promising marker of immune status. The TTV association with the immune status in the immunocompromised transplant population is indisputable. However, we are still looking to understand the impact and the mechanisms behind this interplay. The TTV role as a single or a panel biomarker needs to be evaluated in further independent prospective trials.

**REFERENCES**

1 **Herrmann A**, Sandmann L, Adams O, Herrmann D, Dirks M, Widera M, Westhaus S, Kaiser R, di Cristanziano V, Manns MP, Korth J, Richter N, Anastasiou O, Timm J, von Hahn T, Ciesek S. Role of BK polyomavirus (BKV) and Torque teno virus (TTV) in liver transplant recipients with renal impairment. *J Med Microbiol* 2018; **67**: 1496-1508 [PMID: 30136921 DOI: 10.1099/jmm.0.000823]

2 **Jaksch P**, Kundi M, Görzer I, Muraközy G, Lambers C, Benazzo A, Hoetzenecker K, Klepetko W, Puchhammer-Stöckl E. Torque Teno Virus as a Novel Biomarker Targeting the Efficacy of Immunosuppression After Lung Transplantation. *J Infect Dis* 2018; **218**: 1922-1928 [PMID: 30053048 DOI: 10.1093/infdis/jiy452]

3 **Ruiz P**, Martínez-Picola M, Santana M, Muñoz J, Pérez-Del-Pulgar S, Koutsoudakis G, Sastre L, Colmenero J, Crespo G, Navasa M. Torque Teno Virus Is Associated With the State of Immune Suppression Early After Liver Transplantation. *Liver Transpl* 2019; **25**: 302-310 [PMID: 30375165 DOI: 10.1002/lt.25374]

4 **Enderby C**, Keller CA. An overview of immunosuppression in solid organ transplantation. *Am J Manag Care* 2015; **21**: s12-s23 [PMID: 25734416]

5 **Holt CD**. Overview of Immunosuppressive Therapy in Solid Organ Transplantation. *Anesthesiol Clin* 2017; **35**: 365-380 [PMID: 28784214 DOI: 10.1016/j.anclin.2017.04.001]

6 **Kowalski RJ**, Post DR, Mannon RB, Sebastian A, Wright HI, Sigle G, Burdick J, Elmagd KA, Zeevi A, Lopez-Cepero M, Daller JA, Gritsch HA, Reed EF, Jonsson J, Hawkins D, Britz JA. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. *Transplantation* 2006; **82**: 663-668 [PMID: 16969290 DOI: 10.1097/01.tp.0000234837.02126.70]

7 **Cabrera R**, Ararat M, Soldevila-Pico C, Dixon L, Pan JJ, Firpi R, Machicao V, Levy C, Nelson D, Morelli G. Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients. *Liver Transpl* 2009; **15**: 216-222 [PMID: 19177434 DOI: 10.1002/lt.21666]

8 **Levitsky J**, Asrani SK, Schiano T, Moss A, Chavin K, Miller C, Guo K, Zhao L, Kandpal M, Bridges N, Brown M, Armstrong B, Kurian S, Demetris AJ, Abecassis M; Clinical Trials in Organ Transplantation - 14 Consortium. Discovery and validation of a novel blood-based molecular biomarker of rejection following liver transplantation. *Am J Transplant* 2020; **20**: 2173-2183 [PMID: 32356368 DOI: 10.1111/ajt.15953]

9 **Nishizawa T**, Okamoto H, Konishi K, Yoshizawa H, Miyakawa Y, Mayumi M. A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. *Biochem Biophys Res Commun* 1997; **241**: 92-97 [PMID: 9405239 DOI: 10.1006/bbrc.1997.7765]

10 **International Committee on Taxonomy of Viruses (ICTV)**. Available from: https://talk.ictvonline.org/ Accessed 2020-05-15

11 **Martelli F**, Macera L, Spezia PG, Medici C, Pistello M, Guasti D, Romagnoli P, Maggi F, Giannecchini S. Torquetenovirus detection in exosomes enriched vesicles circulating in human plasma samples. *Virol J* 2018; **15**: 145 [PMID: 30236130 DOI: 10.1186/s12985-018-1055-y]

12 **Focosi D**, Antonelli G, Pistello M, Maggi F. Torquetenovirus: the human virome from bench to bedside. *Clin Microbiol Infect* 2016; **22**: 589-593 [PMID: 27093875 DOI: 10.1016/j.cmi.2016.04.007]

13 **Rezahosseini O**, Drabe CH, Sørensen SS, Rasmussen A, Perch M, Ostrowski SR, Nielsen SD. Torque-Teno virus viral load as a potential endogenous marker of immune function in solid organ transplantation. *Transplant Rev (Orlando)* 2019; **33**: 137-144 [PMID: 30981537 DOI: 10.1016/j.trre.2019.03.004]

14 **Kosulin K**, Kernbichler S, Pichler H, Lawitschka A, Geyeregger R, Witt V, Lion T. Post-transplant Replication of Torque Teno Virus in Granulocytes. *Front Microbiol* 2018; **9**: 2956 [PMID: 30555452 DOI: 10.3389/fmicb.2018.02956]

15 **Kikuchi K**, Miyakawa H, Abe K, Kako M, Katayama K, Fukushi S, Mishiro S. Indirect evidence of TTV replication in bone marrow cells, but not in hepatocytes, of a subacute hepatitis/aplastic anemia patient. *J Med Virol* 2000; **61**: 165-170 [PMID: 10745251 DOI: 10.1002/(SICI)1096-9071(200005)61:1<165::AID-JMV27>3.0.CO;2-F]

16 **Rodríguez-Iñigo E**, Casqueiro M, Bartolomé J, Ortiz-Movilla N, López-Alcorocho JM, Herrero M, Manzarbeitia F, Oliva H, Carreño V. Detection of TT virus DNA in liver biopsies by in situ hybridization. *Am J Pathol* 2000; **156**: 1227-1234 [PMID: 10751348 DOI: 10.1016/S0002-9440(10)64993-0]

17 **Tanaka Y**, Mizokami M, Orito E, Ohno T, Nakano T, Kato T, Iida S, Ueda R. Lack of integrated TT virus (TTV) genomes in cellular DNA in infected human hematopoietic cells. *Leuk Lymphoma* 2000; **38**: 411-417 [PMID: 10830749 DOI: 10.3109/10428190009087033]

18 **Mariscal LF**, López-Alcorocho JM, Rodríguez-Iñigo E, Ortiz-Movilla N, de Lucas S, Bartolomé J, Carreño V. TT virus replicates in stimulated but not in nonstimulated peripheral blood mononuclear cells. *Virology* 2002; **301**: 121-129 [PMID: 12359452 DOI: 10.1006/viro.2002.1545]

19 **Focosi D**, Macera L, Boggi U, Nelli LC, Maggi F. Short-term kinetics of torque teno virus viraemia after induction immunosuppression confirm T lymphocytes as the main replication-competent cells. *J Gen Virol* 2015; **96**: 115-117 [PMID: 25304651 DOI: 10.1099/vir.0.070094-0]

20 **Reshetnyak VI**, Maev IV, Burmistrov AI, Chekmazov IA, Karlovich TI. Torque teno virus in liver diseases: On the way towards unity of view. *World J Gastroenterol* 2020; **26**: 1691-1707 [PMID: 32351287 DOI: 10.3748/wjg.v26.i15.1691]

21 **Magu SK**, Kalghatgi AT, Bhagat MR. Incidence and clinical implication of TT virus in patients with hepatitis and its frequency in blood donors in India. *Med J Armed Forces India* 2015; **71**: 340-344 [PMID: 26663961 DOI: 10.1016/j.mjafi.2015.06.023]

22 **Tri Rinonce H**, Yano Y, Utsumi T, Heriyanto DS, Anggorowati N, Widasari DI, Ghozali A, Utoro T, Lusida MI, Soetjipto, Prasanto H, Hayashi Y. Prevalence and genotypic distribution of GB virus C and torque Teno virus among patients undergoing hemodialysis. *Mol Med Rep* 2017; **15**: 2843–2852 [DOI: 10.3892/mmr.2017.6281]

23 **Elesinnla AR**, Adeleye IA, Ayolabi CI, Bessong PO. Prevalence of torque viruses in HIV-infected and non-HIV-infected Nigerian subjects: analysis of near-full-length genome sequences. *Arch Virol* 2020; **165**: 571-582 [PMID: 32030535 DOI: 10.1007/s00705-020-04538-1]

24 **Vasilyev EV**, Trofimov DY, Tonevitsky AG, Ilinsky VV, Korostin DO, Rebrikov DV. Torque Teno Virus (TTV) distribution in healthy Russian population. *Virol J* 2009; **6**: 134 [PMID: 19735552 DOI: 10.1186/1743-422X-6-134]

25 **Sarairah H**, Bdour S, Gharaibeh W. The Molecular Epidemiology and Phylogeny of Torque Teno Virus (TTV) in Jordan. *Viruses* 2020; **12**: [PMID: 32023916 DOI: 10.3390/v12020165]

26 **Focosi D**, Macera L, Pistello M, Maggi F. Torque Teno virus viremia correlates with intensity of maintenance immunosuppression in adult orthotopic liver transplant. *J Infect Dis* 2014; **210**: 667-668 [PMID: 24688076 DOI: 10.1093/infdis/jiu209]

27 **Giacconi R**, Maggi F, Macera L, Pistello M, Provinciali M, Giannecchini S, Martelli F, Spezia PG, Mariani E, Galeazzi R, Costarelli L, Iovino L, Galimberti S, Nisi L, Piacenza F, Malavolta M. Torquetenovirus (TTV) load is associated with mortality in Italian elderly subjects. *Exp Gerontol* 2018; **112**: 103-111 [PMID: 30223047 DOI: 10.1016/j.exger.2018.09.003]

28 **Béland K**, Dore-Nguyen M, Gagné MJ, Patey N, Brassard J, Alvarez F, Halac U. Torque Teno virus in children who underwent orthotopic liver transplantation: new insights about a common pathogen. *J Infect Dis* 2014; **209**: 247-254 [PMID: 23922368 DOI: 10.1093/infdis/jit423]

29 **Christensen JK**, Eugen-Olsen J, SŁrensen M, Ullum H, Gjedde SB, Pedersen BK, Nielsen JO, Krogsgaard K. Prevalence and prognostic significance of infection with TT virus in patients infected with human immunodeficiency virus. *J Infect Dis* 2000; **181**: 1796-1799 [PMID: 10823787 DOI: 10.1086/315440]

30 **Maggi F**, Ricci V, Bendinelli M, Nelli LC, Focosi D, Papineschi F, Petrini M, Paumgardhen E, Ghimenti M. Changes In CD8+57+ T lymphocyte expansions after autologous hematopoietic stem cell transplantation correlate with changes in torquetenovirus viremia. *Transplantation* 2008; **85**: 1867-1868 [PMID: 18580484 DOI: 10.1097/TP.0b013e31817615e6]

31 **Görzer I**, Jaksch P, Kundi M, Seitz T, Klepetko W, Puchhammer-Stöckl E. Pre-transplant plasma Torque Teno virus load and increase dynamics after lung transplantation. *PLoS One* 2015; **10**: e0122975 [PMID: 25894323 DOI: 10.1371/journal.pone.0122975]

32 **De Vlaminck I**, Khush KK, Strehl C, Kohli B, Luikart H, Neff NF, Okamoto J, Snyder TM, Cornfield DN, Nicolls MR, Weill D, Bernstein D, Valantine HA, Quake SR. Temporal response of the human virome to immunosuppression and antiviral therapy. *Cell* 2013; **155**: 1178-1187 [PMID: 24267896 DOI: 10.1016/j.cell.2013.10.034]

33 **Blatter JA**, Sweet SC, Conrad C, Danziger-Isakov LA, Faro A, Goldfarb SB, Hayes D Jr, Melicoff E, Schecter M, Storch G, Visner GA, Williams NM, Wang D. Anellovirus loads are associated with outcomes in pediatric lung transplantation. *Pediatr Transplant* 2018; **22**: [PMID: 29082660 DOI: 10.1111/petr.13069]

34 **Schiemann M**, Puchhammer-Stöckl E, Eskandary F, Kohlbeck P, Rasoul-Rockenschaub S, Heilos A, Kozakowski N, Görzer I, Kikić Ž, Herkner H, Böhmig GA, Bond G. Torque Teno Virus Load-Inverse Association With Antibody-Mediated Rejection After Kidney Transplantation. *Transplantation* 2017; **101**: 360-367 [PMID: 27525643 DOI: 10.1097/TP.0000000000001455]

35 **Dharnidharka VR**, Ruzinova MB, Chen CC, Parameswaran P, O'Gorman H, Goss CW, Gu H, Storch GA, Wylie K. Metagenomic analysis of DNA viruses from posttransplant lymphoproliferative disorders. *Cancer Med* 2019; **8**: 1013-1023 [PMID: 30697958 DOI: 10.1002/cam4.1985]

36 **Schröter M**, Feucht HH, Schäfer P, Zöllner B, Laufs R, Knödler B. TT virus viremia and liver transplantation: no significant increase of the prevalence. *Blood* 1998; **92**: 4877-4878 [PMID: 9988547 DOI: 10.1182/blood.V92.12.4877]

37 **Burra P**, Masier A, Boldrin C, Calistri A, Andreoli E, Senzolo M, Zorzi M, Sgarabotto D, Guido M, Cillo U, Canova D, Bendinelli M, Pistello M, Maggi F, Palù G. Torque Teno Virus: any pathological role in liver transplanted patients? *Transpl Int* 2008; **21**: 972-979 [PMID: 18564988 DOI: 10.1111/j.1432-2277.2008.00714.x]

38 **Simonetta F**, Pradier A, Masouridi-Levrat S, van Delden C, Giostra E, Morard I, Mueller N, Muellhaupt B, Valli PV, Semmo N, Seebach J, Chalandon Y, Kaiser L, Roosnek E; Swiss Transplant Cohort Study (STCS). Torque Teno Virus Load and Acute Rejection After Orthotopic Liver Transplantation. *Transplantation* 2017; **101**: e219-e221 [PMID: 28263221 DOI: 10.1097/TP.0000000000001723]

39 **Shang D**, Lin YH, Rigopoulou I, Chen B, Alexander GJ, Allain JP. Detection of TT virus DNA in patients with liver disease and recipients of liver transplant. *J Med Virol* 2000; **61**: 455-461 [PMID: 10897063 DOI: 10.1002/1096-9071(200008)61:4<455::aid-jmv7>3.0.co;2-p]

40 **Anastasiou OE**, Theissen M, Verheyen J, Bleekmann B, Wedemeyer H, Widera M, Ciesek S. Clinical and Virological Aspects of HBV Reactivation: A Focus on Acute Liver Failure. *Viruses* 2019; **11** [PMID: 31527514 DOI: 10.3390/v11090863]

**Footnotes**

**Conflict-of-interest statement:** The authors declare they have no potential conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** May 16, 2020

**First decision:** September 18, 2020

**Article in press:** October 9, 2020

**Specialty type:** Transplantation

**Country/Territory of origin:** Croatia

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Ahmed M, Boteon YL, Papalois V **S-Editor:** Zhang H **L-Editor:** Filipodia **P-Editor:** Wang LL

**Table 1 Torque teno virus in the context of liver transplantation: Major key points**

|  |  |  |  |
| --- | --- | --- | --- |
| **Population, *n*** | **TTV prevalence** | **Study key points** | **Ref.** |
| German, adult, 104 | 17.3% pre-LT; 24% post-LT | TTV DNA prevalence not associated with the number of transfused blood products | Schroter *et al*[36], 1998 |
| British, adult, 37 | 16% pre-LT; 46% post-LT | prevalence and TTV viral load increased after LT; no correlation of TTV viral load with liver enzyme levels | Shang *et al*[39], 2000 |
| Italian, adult, 25 | 100% pre-LT | TTV viral load increased significantly after LT (*P* < 0.001); TTV viral load was higher in patients on CNI + AZA/MMF *vs* CNI alone (*P* = 0.04) at 3 mo after LT; no differences in viral load in regard to the etiology of liver disease; no correlation of viral load and TTV genotype with ALT or histological liver damage | Burra *et al*[37], 2008 |
| Canadian, pediatric, 80 | 68% healthy control; 71% pre-LT; 98%-99% post-LT | TTV viral load post-LT was higher than in pre-LT (*P* < 0.001) and healthy controls (*P* < 0.0001); TTV viral load was lower in post-LT chronic hepatitis; TTV viral load decreased during the post-LT follow-up; no correlation between TTV viral load and ALT or number of transfusions; TTV viral load was lower in anti-HEV IgM/IgG positive patients | Béland *et al*[28], 2014 |
| Italian, adult, 46 | 100% pre-LT | TTV viral load increased after LT; low CNI + ECP protocol was associated with the lowest increase in TTV viral load compared to CNI only protocol (*P* < 0.01) or CNI + AZA/MMF protocol (*P* < 0.01) | Focosi *et al*[26], 2014 |
| Swiss, adult, 39 | 74% pre-LT | TTV viral load increased significantly 6 mo post-LT *vs* pre-LT (*P* < 0.0001) and decreased 12 mo post-LT *vs* 6 mo post-LT; 1-yr cumulative incidence of rejection was lower (21%) in TTV positive *vs* 70% in TTV negative patients (*P* = 0.0042) | Simonetta *et al*[37], 2017 |
| German, adult, 136 | 84.6% post-LT (serum); 66.6% post-LT (urine) | TTV viral load negatively correlated with the BKV viral load (*P* = 0.038), but had no impact on renal impairment | Herrmann *et al*[1], 2018 |
| Italian, adult, 134 | 92% pre-LT | TTV viral load progressively increased to a maximum at day 80 post-LT; TTV viral load was higher on Cyc *vs* on Tac (*P* = 0.016); TTV viral load did differ between different Tac levels (within or beyond the therapeutic range); TTV viral load was lower in CMV DNA negative *vs* positive patients (*P* = 0.001); TTV viral load at day 0-10 post-LT predicts CMV reactivation (OR: 1.5, 95%CI: 1.0-2.3) | Maggi *et al*[30], 2018 |
| Spanish, adult, 63 | 93.7% pre-LT; 100% post-LT | TTV viral load progressively increased peaking at month 3 and then decreased during months 6-12 post-LT; patients on triple IS had higher viremia *vs* on double IS (*P* < 0.001); no differences in TTV viremia according to the type of CNI; TTV viral load was lower during ACR (4.41 *vs* 5.95 log10 copies/mL; *P* = 0.002) and higher during CMV infections (5.79 *vs* 6.59 log10 copies/mL; *P* = 0.009); the area under the ROC curve of TTV viral load for moderate ACR was 0.869, with a sensitivity and negative predictive value of 100%, respectively, for a cut-off point of 4.75 log10 copies/mL; TTV viral load did not differ in long-term or tolerant patients and healthy controls | Ruiz *et a**l*[3], 2019 |
| German, immunosuppressed patients with HBV reactivation, 87 (20 LT recipients) |  | TTV viral load did not differ between patients with ALF *vs* non-ALF; no differences in TTV viral loads diagnosed during *vs* after IS (*P* = 0.740), nor after HBV resolution *vs* chronic HBV (*P* = 0.727) | Anastasiou *et al*[40], 2019 |

ACR: Acute cellular rejection; ALF: Acute liver failure; ALT: Alanine aminotransferase; AZA: Azathioprine; BKV: BK virus; CI; Confidence interval; CMV: Cytomegalovirus; CNI: Calcineurin inhibitor; Cyc: Cyclosporine; DNA: Deoxyribonucleic acid; ECP: Extracorporeal photopheresis; HBV: Hepatitis B virus; Ig: Immunoglobulin; IS: Immunosuppression; LT: Liver transplant; MMF: Mycophenolate-mofetil; OR: Odds ratio; Tac: Tacrolimus; TTV: Torque teno virus.